Australia markets closed

BridgeBio Pharma, Inc. (BBIO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
30.09-0.95 (-3.06%)
At close: 04:00PM EDT
30.11 +0.02 (+0.07%)
After hours: 05:46PM EDT

BridgeBio Pharma, Inc.

3160 Porter Drive
Suite 250
Palo Alto, CA 94304
United States
650 391 9740

Full-time employees550

Key executives

NameTitlePayExercisedYear born
Dr. Neil Kumar Ph.D.Co-Founder, President, CEO & Director1.53MN/A1979
Dr. Charles J. Homcy M.D.Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director563.2kN/A1948
Dr. Frank P. McCormick Ph.D.Co-Founder, Chairman of Oncology & Director542.78kN/A1950
Dr. Brian C. Stephenson C.F.A., Ph.D.CFO & Secretary1.15MN/A1981
Dr. Richard H. Scheller Ph.D.Chairman of Research & Development509.62kN/A1953
Dr. Uma Sinha Ph.D.Chief Scientific Officer1.31MN/A1958
Grace RauhVice President of CommunicationsN/AN/AN/A
Mr. Eli M. Wallace Ph.D.Chief Scientific Officer of OncologyN/AN/A1967
Dr. Thomas Trimarchi Ph.D.Chief Product OfficerN/AN/AN/A
Dr. Eric Michael David J.D., M.D., Ph.D.Chief Executive Officer of Gene TherapyN/AN/A1972
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Corporate governance

BridgeBio Pharma, Inc.’s ISS governance QualityScore as of 1 May 2024 is 10. The pillar scores are Audit: 3; Board: 10; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.